Add office photos
Engaged Employer
Zydus Lifesciences
4.1
based on 6k Reviews
Video summary
Company Overview
Associated Companies
Company Locations
Working at Zydus Lifesciences
Company Summary
In 1995 we dedicated ourselves to the welfare of people and depicted our commitment with a heart-to-heart portrait. Today, with our evolved brand identity, this commitment emerges stronger than ever.
Overall Rating
4.1/5
based on 6k reviews
5% above
industry average
Highly rated for
Salary, Job security, Skill development
Work Policy
Work from office
83% employees reported
Monday to Saturday
59% employees reported
Strict timing
56% employees reported
No travel
47% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
358 employees reported
Office cab/shuttle
348 employees reported
Health insurance
324 employees reported
Cafeteria
128 employees reported
View all benefits
About Zydus Lifesciences
Founded in1952 (73 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersAhmedabad, India, India
Websitezyduslife.com
Primary Industry
Other Industries
View in video summary
Zydus Lifesciences Limited formerly knowns as Cadila Healthcare Limited, a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. From formulations to active pharmaceutical ingredients. Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions. One of the salient features of Zydus is its rich history and lineage. The origin of the company dates all the way back to the 1950s. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals. In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover of Rs. 250 crores in 1995 the group witnessed significant financial growth and registered a turnover of over Rs. 15,000 crores in FY-21. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe.
Mission: To unlock new possibilities in life-sciences through quality healthcare solutions that impact lives.
Vision: To be a global life-sciences company transforming lives through pathbreaking discoveries.
Zydus Lifesciences Ratings
based on 6k reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
3.2k
4
1.5k
3
647
2
267
1
424
Category Ratings
4.0
Salary
3.9
Job security
3.9
Skill development
3.8
Company culture
3.8
Work-life balance
3.8
Work satisfaction
3.7
Promotions
Zydus Lifesciences is rated 4.1 out of 5 stars on AmbitionBox, based on 6k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Zydus Lifesciences
based on 5.4k reviews
4.0
Rated by 387 Women
Rated 4.0 for Job security and 3.8 for Skill development
4.1
Rated by 5k Men
Rated 4.0 for Salary and 3.9 for Job security
Work Policy at Zydus Lifesciences
based on 601 reviews in last 6 months
Work from office
83%
Hybrid
10%
Permanent work from home
7%
Zydus Lifesciences Reviews
Top mentions in Zydus Lifesciences Reviews
+ 5 more
Compare Zydus Lifesciences with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.1/5 based on 6k reviews | 4.0/5 based on 5.8k reviews | 4.1/5 based on 6.9k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Salary Skill development Job security | Salary Skill development Job security | Skill development Salary Work-life balance | Skill development Work-life balance Salary |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 83% employees reported | Work from office 82% employees reported | Work from office 73% employees reported | - |
Rating by Women Employees | 4.0 Good rated by 387 women | 4.0 Good rated by 441 women | 4.1 Good rated by 680 women | - no rating available |
Rating by Men Employees | 4.1 Good rated by 5k men | 4.0 Good rated by 5k men | 4.1 Good rated by 5.8k men | - no rating available |
Job security | 3.9 Good | 3.8 Good | 3.7 Good | 4.0 Good |
View more
Zydus Lifesciences Salaries
Zydus Lifesciences salaries have received with an average score of 4.0 out of 5 by 6k employees.
Deputy Manager
(869 salaries)
Unlock
₹7.5 L/yr - ₹18.6 L/yr
Officer
(854 salaries)
Unlock
₹1.6 L/yr - ₹6.8 L/yr
Technical Assistant
(298 salaries)
Unlock
₹1.8 L/yr - ₹7.2 L/yr
Area Business Manager
(207 salaries)
Unlock
₹3.8 L/yr - ₹12 L/yr
Production Officer
(206 salaries)
Unlock
₹1.2 L/yr - ₹5.4 L/yr
Research Associate
(200 salaries)
Unlock
₹1.6 L/yr - ₹9.6 L/yr
Medical Representative
(195 salaries)
Unlock
₹1.6 L/yr - ₹6.5 L/yr
Senior Associate
(184 salaries)
Unlock
₹2.7 L/yr - ₹10.5 L/yr
Executive Production
(166 salaries)
Unlock
₹3.1 L/yr - ₹7.9 L/yr
Therapy Manager
(144 salaries)
Unlock
₹3.4 L/yr - ₹11.2 L/yr
Zydus Lifesciences Interview Questions
Interview questions by designation
Top Zydus Lifesciences interview questions and answers
Get interview-ready with top interview questions
Zydus Lifesciences Jobs
Popular Designations Zydus Lifesciences Hires for
Popular Skills Zydus Lifesciences Hires for
Current Openings
Zydus Lifesciences News
View all
Stocks To Watch Today: Zydus Lifesciences, Gensol Engineering, Wipro, GMR Airports, Route Mobile
- Zydus Lifesciences received FDA approval for Dasatinib Tablets.
- Gensol Engineering downgraded due to ongoing delays in debt servicing.
- Galaxy Surfactants entered into a strategic collaboration for engineering services.
- Wipro launched TelcoAI360 to transform operations for telecom companies.
Bloomberg Quint | 6 Mar, 2025
Stock Market Today: All You Need To Know Going Into Trade On March 6
- The NSE Nifty 50 rose by 1.15% to 22,337.30, and the BSE Sensex closed 1.01% higher at 73,730.23 on Wednesday.
- Foreign investors continued selling, while domestic institutional investors bought equities worth Rs 3,370.60 crore.
- Stocks to watch: Zydus Lifesciences got FDA approval, Gensol Engineering's rating was downgraded, and other companies made key announcements.
- Trading tweaks include price band changes and stocks entering and leaving the ASM framework.
- Insider trades were noted in companies like NCC, Rain Industries, and West Coast Paper Mills.
- Promoters pledged shares in companies like Go Fashion (India) and Fusion Finance.
- In F&O cues, Nifty March futures were up with call and put open interest details, and Manappuram Finance was in the ban period.
- Notable upcoming meetings include Titan with investors and analysts, and GAIL (India) with investors and analysts.
- The Indian Rupee strengthened to 86.96 per US Dollar supported by falling crude oil prices.
- Overall, the market closed positively, with various company updates and market indicators signaling ongoing activity and investor interest.
Bloomberg Quint | 6 Mar, 2025
Zydus Lifesciences' Dasatinib Tablets Get USFDA Approval, To Manufacture At Ahmedabad Unit
- Zydus Lifesciences Ltd. has received USFDA approval to manufacture Dasatinib tablets.
- The tablets will be manufactured at Zydus Lifesciences' unit in Ahmedabad.
- Dasatinib tablets are used to treat chronic myeloid leukemia and other conditions.
- Zydus Lifesciences' consolidated net profit rose nearly 30% in Q3 FY2024-25.
Bloomberg Quint | 5 Mar, 2025
Zydus to develop first-ever typhoid-shigella combo vaccine with Gates support
- Zydus Lifesciences is set to develop the first-ever typhoid-shigella combo vaccine with support from the Gates Foundation.
- The vaccine aims to protect children under five years against the deadly enteric diseases typhoid and shigella.
- Zydus will utilize its WHO-prequalified Typhoid conjugate vaccine (ZyVac TCV) and collaborate with a partner for the shigella vaccine component.
- The collaboration has the potential to contribute significantly to protecting children worldwide and addressing unmet needs in affordable vaccines for enteric diseases.
HinduBusinessLine | 4 Mar, 2025
Tech Mahindra To Zydus Lifesciences — Here Are Top Stock Picks For March 2025 By DRChoksey
- DRChoksey lists six top stocks that investors can buy with a potential upside of up to 44%.
- The stocks meet the criteria of sound business, consistent strong financials, high growth potential, high return on invested capital, and strong brand value.
- The management of these companies is also considered strong and effective with high corporate access.
- Investors can subscribe to unlock the full story and access the benefits of being a subscriber.
Bloomberg Quint | 4 Mar, 2025
Stocks that will see action today: February 27, 2025
- B Santhanam, CEO of Saint-Gobain Asia Pacific and Chairman of Saint-Gobain India, announced retirement after over four decades with the company.
- Wipro to invest $200 million in Wipro Ventures to support technology start-ups, accelerating funding for early to mid-stage companies.
- Star Health expands Home Health Care to 100 locations, covering 85% of its customer base with doorstep medical care service.
- Assam Government initiates ropeway project with GR Infraprojects, with a proposed investment of ₹270 crore.
- Mastek secures contracts worth $85 million over 2 years from a UK public service department for digital transformation services.
- Zydus Lifesciences introduces vaccine for protection against a new strain of influenza virus, offering protection against four virus strains.
- IndusInd Bank receives ₹21.62 crore demand notice from tax authorities for alleged GST short payment.
- NGL Fine-Chem settles shareholding disclosure violation case with SEBI by paying ₹92.21 lakh along with promoters.
- SEBI imposes ₹5.05 crore penalty on Indian Clearing Corporation Ltd for non-compliance with cyber security and disaster recovery framework.
- Emcure Pharmaceuticals receives two observations from USFDA after cGMP inspection of its Pune-based API manufacturing facility.
HinduBusinessLine | 27 Feb, 2025
Zydus Lifesciences to launch VaxiFlu-4 for new influenza strain
- Pharmaceutical company Zydus Lifesciences is set to launch VaxiFlu-4, a quadrivalent inactivated influenza vaccine.
- The vaccine, developed at the Vaccine Technology Centre in Ahmedabad, covers strains of both influenza A and influenza B, providing broader protection.
- VaxiFlu-4 has been cleared by the Central Drug Laboratory and is being marketed by Zydus Vaxxicare, a division of the group focusing on preventives.
- Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, emphasized the need for affordable, high-quality vaccines to improve public health.
HinduBusinessLine | 26 Feb, 2025
Stock Market Today: All You Need To Know Going Into Trade On Feb. 17
- The Indian equity benchmark indices closed lower on Friday, recording their longest losing streak in two years.
- Foreign portfolio investors continued as net sellers of Indian equities, while domestic institutional investors remained net buyers on Friday.
- The Indian rupee strengthened by six paise, closing at 86.83 against the US Dollar on Friday.
- Earnings highlights after market hours include companies like Northern Arc Capital, Glenmark Pharma, Cupid, Swan Energy, Easy Trip Planners, and more.
- Stocks to watch include JSW Energy, Zydus Lifesciences, Vodafone Idea, Alembic Pharmaceuticals, and Bharat Heavy Electricals, among others.
- In the IPO space, Hexaware Technologies saw good subscription on day three, while Quality Power Electrical Equipments saw lower subscription on day one.
- Insider trading activities were noted in companies like Nahar Spinning Mills, Kilburn Engineering, Paisalo Digital, and Alembic Pharmaceuticals.
- Trading tweaks included price band changes, ex-dividend dates, and stocks moving in and out of the short-term ASM framework.
- In F&O cues, Nifty Feb futures saw downward movement, and securities in the ban period included Deepak Nitrite.
- The Indian rupee strengthened further against the US Dollar at market open on Friday, reflecting positive market sentiment and possible support from the RBI.
Bloomberg Quint | 17 Feb, 2025
Trade Setup For Feb. 17: Nifty 50 Finds Key Resistance At 23,300 Levels
- Nifty 50 is facing key resistance at 23,300 levels, with a potential near-term bottom reversal pattern upon a move above this level.
- The Nifty 50 formed a red candle on daily and weekly charts, indicating a lack of strength in the upside recovery.
- A triple bottom around 22,780 on the daily scale suggests strong support for the Nifty 50.
- The 21-Day Simple Moving Average at 23,260 makes the 23,260-23,300 zone an immediate hurdle.
- Bank Nifty also showed weakness, with a recommendation to monitor levels closely for trading opportunities.
- Indian equity indices closed lower, marking the longest losing streak in two years, influenced by certain stocks.
- Nifty Realty, Nifty Midcap 150, and Nifty Oil and Gas experienced significant declines during the week.
- Trading cues and FII/DII activity indicated market trends, with focus on key levels and open interest for Nifty futures.
- Major stocks in the news included Bharat Heavy Electricals, JSW Energy, Zydus Lifesciences, Vodafone Idea, and their developments.
- Indian rupee strengthened against the US dollar, reflecting positive market sentiment and potential RBI support.
Bloomberg Quint | 16 Feb, 2025
Zydus Lifesciences Q3 Review — One Offs Impact Margins; Systematix Recommends 'Hold', Revises Target Price
- Zydus Lifesciences Q3 revenue stood at Rs 52,691 million, up 17.0% YoY.
- One-offs impact margins; competition causes decline in Asacol HD sales.
- Systematix recommends 'Hold' and revises target price for Zydus Lifesciences.
- Pivotal clinical data on Saroglitazar in primary biliary cholangitis to shape long-term growth opportunity.
Bloomberg Quint | 6 Feb, 2025
Powered by
Zydus Lifesciences Subsidiaries
Zydus Healthcare
4.0
• 625 reviews
Zydus Hospital
4.3
• 241 reviews
German Remedies
3.9
• 88 reviews
Zydus Animal Health
3.7
• 58 reviews
Liva Pharmaceuticals
3.5
• 39 reviews
Zydus Pharmaceuticals
4.5
• 13 reviews
Report error
Compare Zydus Lifesciences with
Biocon Limited
3.9
Torrent Pharmaceuticals
3.9
Lupin
4.2
Glenmark Pharmaceuticals
3.9
Aurobindo Pharma
4.0
DIVI'S Laboratories
3.7
Alembic Pharmaceuticals
4.0
Dr. Reddy's
4.0
Intas Pharmaceuticals
4.1
Hetero
3.9
Viatris
4.2
Abbott
4.1
Alkem Laboratories
3.9
Ipca Laboratories
3.9
Mankind Pharma
3.9
MSN Laboratories
3.7
Ajanta Pharma
4.1
Akums Drugs & Pharmaceuticals Limited
4.4
GlaxoSmithKline Pharmaceuticals
4.1
Pfizer
4.0
Contribute & help others!
You can choose to be anonymous
Companies Similar to Zydus Lifesciences
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 5.8k reviews
Cipla
Manufacturing, Pharma
4.1
• 6.9k reviews
DRJ & CO
Architecture & Interior Design
5.0
• 1 reviews
Biocon Limited
Biotech & Life sciences, Biotechnology
3.9
• 1.9k reviews
Torrent Pharmaceuticals
Pharma
3.9
• 2.5k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.2
• 6k reviews
Glenmark Pharmaceuticals
Pharma
3.9
• 2.9k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 4.8k reviews
DIVI'S Laboratories
Pharma
3.7
• 1.4k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.1k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 6.8k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.4k reviews
Zydus Lifesciences FAQs
When was Zydus Lifesciences founded?
Zydus Lifesciences was founded in 1952. The company has been operating for 73 years primarily in the Pharma sector.
Where is the Zydus Lifesciences headquarters located?
Zydus Lifesciences is headquartered in Ahmedabad, India. It operates in 2 cities such as Ahmedabad, Mumbai. To explore all the office locations, visit Zydus Lifesciences locations.
How many employees does Zydus Lifesciences have in India?
Zydus Lifesciences currently has more than 26,000+ employees in India. Production, Manufacturing & Engineering department appears to have the highest employee count in Zydus Lifesciences based on the number of reviews submitted on AmbitionBox.
Does Zydus Lifesciences have good work-life balance?
Zydus Lifesciences has a Work-Life Balance Rating of 3.8 out of 5 based on 5,900+ employee reviews on AmbitionBox. 78% employees rated Zydus Lifesciences 4 or above, while 22% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Zydus Lifesciences work-life balance reviews for more details
Is Zydus Lifesciences good for career growth?
Career growth at Zydus Lifesciences is rated fairly well, with a promotions and appraisal rating of 3.7. 78% employees rated Zydus Lifesciences 4 or above, while 22% employees rated it 3 or below on promotions/appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Zydus Lifesciences promotions/appraisals reviews for more detailed insights.
What are the pros of working in Zydus Lifesciences?
Working at Zydus Lifesciences offers several advantages that make it an appealing place for employees. The company is highly rated for salary & benefits, job security and skill development, based on 5,900+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
